PRNewsWire
15 Jul 2026, 01:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
A patient receiving Erasca's ERAS-0015 treatment died one month after administration. — Patient death in clinical trials is a critical safety failure that can lead to FDA holds or total project termination.
-0.90Revolution Medicines (RevMed) has accused Erasca of patent infringement and misappropriation of trade secrets regarding ERAS-0015. — Intellectual property disputes threaten the company's ability to commercialize its primary drug candidate and its competitive 'moat'.
-0.70Erasca is facing a securities class action lawsuit alleging it misled investors about the safety and IP protection of ERAS-0015. — Litigation creates financial liabilities and reputational damage, though the primary price drivers are the underlying drug failures.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company faces a securities class action lawsuit following a 48% stock drop triggered by patent infringement allegations and a patient death.
The company is actively challenging a competitor's intellectual property and accusing them of misappropriating trade secrets.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
